Research Summary

Analyzed using Evidence Intelligence™

Omega-3 improves periodontal health and glycemic control in diabetes

Key finding

Omega-3FAs-treated group recorded a more statistically significant improvement in clinical parameters compared to the control group.

This study examined the effects of omega-3 fatty acids as an adjunct to nonsurgical periodontal therapy in periodontitis patients with type II diabetes, finding significant improvements in various clinical parameters.

Evidence strength

Moderate confidence

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Some Concerns bias

Last updated July 5, 2026

Quick read

Study at a glance

The essential study design details in one scan.

Population

Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes

Intervention

Omega-3 Fatty Acid Supplementation

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Primary outcome

Plaque Index (PI)

Comparator

Control group (nonsurgical periodontal therapy only)

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

Clinical relevance

The findings suggest that incorporating omega-3 fatty acids into the treatment regimen for periodontitis in diabetic patients could enhance both periodontal and metabolic outcomes, potentially leading to improved overall health and reduced complications associated with diabetes.

Keep in mind

The study's sample size may limit the generalizability of the findings. The duration of the study may not capture long-term effects. Potential confounding factors were not fully controlled.

Published in

Journal Reference

Publication details and source links for this paper.

Dalia G, Ahmed A, Ahmed H, Ayman E. The adjunctive use of omega-3 fatty acids with nonsurgical periodontal therapy in periodontitis patients with type II diabetes. International Journal of Dentistry. 2025;2025:7927250. doi:10.1155/ijod/7927250

View DOI View on PubMed View on PMC

Save this study and add notes to your research library.

Main Effects

Omega-3FAs treatment led to a significant decrease in HbA1c levels by 2.1% (p=0.001).

The omega-3FAs group showed a reduction in probing depth by 1.67 mm (p=0.001).

Clinical attachment loss improved significantly by 3 mm in the omega-3FAs group (p=0.001).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Omega-3 Fatty Acid Supplementation and Clinical attachment level, GCF Chemerin, Gingival Index (GI), and 4 more.

This study contributes evidence to

Intervention

Omega-3 Fatty Acid Supplementation

Outcome

Clinical attachment level

Evidence topic

HbA1c Reduction

Primary intervention

Omega-3 Fatty Acid Supplementation

Primary outcomes

Clinical attachment level
GCF Chemerin
Gingival Index (GI)

Evidence topics

HbA1c Reduction

Primary intervention

Omega-3 Fatty Acid Supplementation

Primary outcomes

Clinical attachment level GCF Chemerin Gingival Index (GI)

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 63

Why it is useful

Contributes to 7 evidence relationships
Includes primary outcome data
Linked to 1 direct semantic evidence topic

Topic contributions

Evidence topic

Omega-3 Fatty Acid Supplementation → Serum Chemerin

Evidence profile

StrongDecreaseMetabolic Health

Unlock full evidence details

Unlock full evidence analysis

Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.

Evidence Suggest

Omega-3FAs treatment resulted in a significant reduction in serum chemerin levels after 6 months.
Participants receiving omega-3FAs showed improved plaque and gingival indices compared to controls.
The omega-3FAs group experienced a significant decrease in clinical attachment loss.

Who this applies to

Adults with type II diabetes and periodontitis.
Patients undergoing nonsurgical periodontal therapy.

Keep in Mind

Results may not apply to populations outside the study's demographic.
The study did not assess the long-term effects beyond 6 months.
Further research is needed to confirm these findings in larger, diverse populations.

Between the Lines

The study's sample size may limit the generalizability of the findings.
The duration of the study may not capture long-term effects.
Potential confounding factors were not fully controlled.

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on Omega-3 Fatty Acid Supplementation and Clinical attachment level, Omega-3 Fatty Acid Supplementation and GCF Chemerin.

Related evidence relationships

Explore in Evidence Archive

This study contributes to the evidence on the following intervention-outcome relationships.

Omega-3 Fatty Acid SupplementationClinical attachment level

Supplements

1 studies

Detailed evidence

Omega-3 Fatty Acid SupplementationGCF Chemerin

Supplements

Latest published studies

recency_collection

Published within the last 2 years.

Generated from the study's connected evidence using Evidence Intelligence™.

Does Omega-3 Fatty Acid Supplementation improve clinical attachment level?

Emerging Evidence

Omega-3 Fatty Acid Supplementation appears to improve Clinical attachment level.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Clinical attachment level
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does Omega-3 Fatty Acid Supplementation improve gcf chemerin?

Emerging Evidence

Omega-3 Fatty Acid Supplementation appears to improve GCF Chemerin.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
GCF Chemerin
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does Omega-3 Fatty Acid Supplementation improve gingival index (gi)?

Emerging Evidence

Omega-3 Fatty Acid Supplementation appears to improve Gingival Index (GI).

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Gingival Index (GI)
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does Omega-3 Fatty Acid Supplementation improve HbA1c?

Emerging Evidence

Omega-3 Fatty Acid Supplementation appears to improve HbA1c.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, archive views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

HbA1c Reduction Evidence Hub

Explore in archive

Open broader archive views for this relationship.

All studies on Omega-3 Fatty Acid Supplementation and Clinical attachment level All studies on Omega-3 Fatty Acid Supplementation and GCF Chemerin All studies on Omega-3 Fatty Acid Supplementation and Gingival Index (GI)All studies on Omega-3 Fatty Acid Supplementation and HbA1c

Related research

Read related research summaries.

HRS-7535 improves glycemic control in adults with type 2 diabetes Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetes GLP-1 agonists reduce heart fat thickness in diabetes.Metformin and glimepiride with basal insulin lowered HbA1c the most Natural products may improve glycemic control in type 2 diabetes

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.